Total Payments
$2,561
2024 Payments
$188.22
Companies
24
Transactions
108
Medicare Patients
891
Medicare Billing
$169,676
Payment Breakdown by Category
Food & Beverage$2,561 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,561 | 108 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $552.08 | 24 | $0 (2024) |
| Janssen Biotech, Inc. | $337.78 | 19 | $0 (2023) |
| Gilead Sciences, Inc. | $250.24 | 8 | $0 (2024) |
| GENZYME CORPORATION | $235.55 | 9 | $0 (2023) |
| Ethicon US, LLC | $121.16 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $121.16 | 6 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $115.43 | 1 | $0 (2022) |
| SCILEX PHARMACEUTICALS INC. | $103.41 | 6 | $0 (2021) |
| Ferring Pharmaceuticals Inc. | $100.17 | 2 | $0 (2023) |
| Celgene Corporation | $97.35 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $188.22 | 4 | Gilead Sciences, Inc. ($129.35) |
| 2023 | $777.87 | 37 | ABBVIE INC. ($159.38) |
| 2022 | $1,406 | 56 | ABBVIE INC. ($333.83) |
| 2021 | $56.79 | 3 | Bioventus LLC ($41.84) |
| 2020 | $132.07 | 8 | SCILEX PHARMACEUTICALS INC. ($88.46) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $129.35 | General |
| Category: INFLAM | ||||||
| 10/23/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: IMMUNOLOGY | ||||||
| 01/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: IMMUNOLOGY | ||||||
| 07/22/2023 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: IMMUNOLOGY | ||||||
| 07/17/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $3.16 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/14/2023 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: Immunology | ||||||
| 06/28/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Gastroenterology | ||||||
| 06/27/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/26/2023 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: IMMUNOLOGY | ||||||
| 06/22/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.07 | General |
| Category: Neuroscience | ||||||
| 06/19/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: Gastroenterology | ||||||
| 06/01/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/01/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/30/2023 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Immunology | ||||||
| 05/24/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: Immunology | ||||||
| 05/23/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.74 | General |
| 05/23/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Immunology | ||||||
| 05/15/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Immunology | ||||||
| 05/15/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.98 | General |
| Category: Neuroscience | ||||||
| 05/05/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: VIROLOGY | ||||||
| 04/19/2023 | Amgen Inc. | AMJEVITA (Biological), AVSOLA | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Inflammation | ||||||
| 04/18/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.23 | General |
| Category: Immunology | ||||||
| 04/14/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.18 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 120 | 131 | $22,335 | $8,359 |
| 2022 | 4 | 65 | 1,047 | $58,130 | $15,594 |
| 2021 | 9 | 301 | 5,972 | $363,954 | $103,501 |
| 2020 | 8 | 405 | 606 | $175,472 | $42,222 |
Total Patients
891
Total Services
7,756
Medicare Billing
$169,676
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 40 | $5,480 | $2,264 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 28 | $5,656 | $2,091 | 37.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $6,293 | $1,951 | 31.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $3,430 | $1,511 | 44.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 16 | 18 | $1,476 | $543.06 | 36.8% |
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | Office | 2022 | 15 | 925 | $40,545 | $10,831 | 26.7% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2022 | 17 | 35 | $10,780 | $2,977 | 27.6% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 19 | 41 | $6,765 | $1,781 | 26.3% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2022 | 14 | 46 | $40.42 | $4.61 | 11.4% |
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | Office | 2021 | 35 | 5,025 | $222,688 | $67,985 | 30.5% |
| 77002 | Fluoroscopic guidance for insertion of needle | Office | 2021 | 41 | 196 | $59,431 | $16,423 | 27.6% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 40 | 206 | $33,589 | $9,266 | 27.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 48 | 48 | $24,884 | $5,237 | 21.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 30 | 41 | $11,950 | $2,614 | 21.9% |
| 73560 | X-ray of knee, 1 or 2 views | Office | 2021 | 38 | 51 | $3,614 | $1,211 | 33.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 20 | $7,322 | $589.48 | 8.1% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 12 | 12 | $314.64 | $138.60 | 44.1% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2021 | 37 | 373 | $161.05 | $37.11 | 23.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 162 | 308 | $99,421 | $20,698 | 20.8% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 58 | 73 | $21,462 | $8,212 | 38.3% |
| 80307 | Testing for presence of drug | Office | 2020 | 78 | 105 | $24,990 | $6,447 | 25.8% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2020 | 16 | 17 | $11,628 | $1,938 | 16.7% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 11 | 11 | $4,059 | $1,701 | 41.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $7,964 | $1,507 | 18.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 16 | 20 | $4,480 | $1,013 | 22.6% |
About Jennifer Flickinger
Jennifer Flickinger is a Pain Management healthcare provider based in Colorado Springs, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2019. The National Provider Identifier (NPI) number assigned to this provider is 1255986741.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jennifer Flickinger has received a total of $2,561 in payments from pharmaceutical and medical device companies, with $188.22 received in 2024. These payments were reported across 108 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($2,561).
As a Medicare-enrolled provider, Flickinger has provided services to 891 Medicare beneficiaries, totaling 7,756 services with total Medicare billing of $169,676. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Management
- Other Specialties Pain Medicine, Orthotic Fitter
- Location Colorado Springs, CO
- Active Since 08/02/2019
- Last Updated 03/17/2022
- Taxonomy Code 163WP0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255986741
Products in Payments
- STELARA (Biological) $323.99
- DUPIXENT (Biological) $235.55
- MAVYRET (Drug) $176.20
- CREON (Drug) $133.89
- Livdelzi (Drug) $129.35
- REMICADE (Biological) $129.22
- ENTYVIO (Biological) $121.16
- ZTLido (Drug) $103.41
- ZEPOSIA (Drug) $97.35
- XIFAXAN (Drug) $86.19
- INTERSTIM (Device) $81.97
- RINVOQ (Biological) $76.90
- Talicia (Drug) $73.16
- SKYRIZI (Biological) $67.30
- LINZESS (Drug) $50.95
- IBSRELA (Drug) $34.15
- OCALIVA (Drug) $32.86
- BELBUCA (Drug) $31.56
- HUMIRA (Biological) $23.81
- Durolane (Device) $23.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.